# EDGAR Filing Document

**Accession Number:** 0001576885
**File Stem:** 0001628280-25-050800
**Filing Date:** 2025-11
**Character Count:** 15861
**Document Hash:** 6a02dcc49fd026988279198fb3ff67cb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-050800.hdr.sgml**: 20251110

**ACCESSION NUMBER**: 0001628280-25-050800

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20251106

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251110

**DATE AS OF CHANGE**: 20251110

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Acumen Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001576885
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 364108129
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40551
- **FILM NUMBER:** 251464525

**BUSINESS ADDRESS:**
- **STREET 1:** 1210-1220 WASHINGTON STREET
- **STREET 2:** SUITE 210
- **CITY:** NEWTON
- **STATE:** MA
- **ZIP:** 02465
- **BUSINESS PHONE:** 617-344-4190

**MAIL ADDRESS:**
- **STREET 1:** 1210-1220 WASHINGTON STREET
- **STREET 2:** SUITE 210
- **CITY:** NEWTON
- **STATE:** MA
- **ZIP:** 02465

?xml version='1.0' encoding='ASCII'? abos-20251106

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

____________________________

**FORM 8-K**

____________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 6, 2025**

____________________________

**Acumen Pharmaceuticals, Inc.**

**(Exact name of Registrant as Specified in Its Charter)**

____________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40551** | **36-4108129** |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

---

| | |
|:---|:---|
| **1210-1220 Washington Street, Suite 210**<br>**Newton, Massachusetts** | **02465** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**(617) 344-4190**

**(Registrant's Telephone Number, Including Area Code)**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

____________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange** <br>**on which registered** |
| **Common Stock, $0.0001 par value** | **ABOS** | **The Nasdaq Global Select Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 5.02&nbsp;&nbsp;&nbsp;&nbsp;Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.**

On November 6, 2025, the Board of Directors (the "**Board**") of Acumen Pharmaceuticals, Inc. (the "**Company**") approved the appointment of Dr. George Golumbeski to serve as a director of the Board, effective November 6, 2025 (the "**Effective Date**"). Dr. Golumbeski has been designated a Class II director to hold office until the Company's 2026 Annual Meeting of Stockholders, or until his successor has been duly elected and qualified, or until his earlier death, resignation or removal. The Board has determined that Dr. Golumbeski is "independent" pursuant to the rules of The Nasdaq Stock Market LLC and other governing laws and applicable regulations. In addition, Dr. Golumbeski has also been appointed to replace Dr. Sean Stalfort as Chairman of the Board.

Dr. Golumbeski has served as a partner at DROIA Ventures, a venture capital firm focused on therapeutics for oncology and genetic disease, since October 2020 and previously served as the President and Head of Corporate Development for GRAIL, Inc. from August 2018 to September 2019. From 2009 to April 2018, Dr. Golumbeski served as Executive Vice President of Business Development for Celgene Corporation ("**Celgene**"). Prior to Celgene, Dr. Golumbeski was Vice President of Business Development, Licensing, and Strategy at Novartis. Dr. Golumbeski has served on the board of Shattuck Labs, Inc. since January 2018, and he serves on the boards of directors of various private companies. He also previously served on the boards of directors of Sage Therapeutics, Inc., MorphoSys AG and Enanta Pharmaceuticals, Inc. Dr. Golumbeski received a B.A. in Biology from the University of Virginia and a Ph.D. in genetics from the University of Wisconsin—Madison. The Board believes Dr. Golumbeski is qualified to serve as a director based on his significant experience in research and development, business development and leadership at various pharmaceutical companies.

In accordance with the Company's Non-Employee Director Compensation Policy, as amended on March 24, 2022 and further amended on March 6, 2025 (the "**Policy**") and filed as Exhibit 10.4 to the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 27, 2025, Dr. Golumbeski's compensation for his services as a non-employee director will be consistent with that of the Company's other non-employee directors. In accordance with the Policy, on November 6, 2025, Dr. Golumbeski was granted an initial stock option to purchase 50,000 shares of the Company's common stock with an exercise price equal to the closing price of the Company's common stock on the date of grant. The option will have a ten-year term, and will vest in equal monthly installments over a three-year period, such that the option will be fully vested on the third anniversary of the date of grant, subject to Dr. Golumbeski's continuous service through each such vesting date. In addition, in accordance with the Policy, Dr. Golumbeski will be entitled to receive a $40,000 annual retainer for his service on the Board and a $30,000 annual retainer for his service as Chairman.

The Company has also entered into its standard indemnification agreement for directors with Dr. Golumbeski.

There are no arrangements or understandings between Dr. Golumbeski and any other person pursuant to which Dr. Golumbeski was selected as a director, and there are no transactions in which the Company is a party and in which Dr. Golumbeski has a material interest subject to disclosure under Item 404(a) of Regulation S-K.

**Item 7.01 &nbsp;&nbsp;&nbsp;&nbsp;Regulation FD Disclosure.**

On November 10, 2025, the Company issued a press release announcing the appointment of Dr. Golumbeski as a director of the Board. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing, except as otherwise expressly stated in such filing.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

**(d).Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | <u>[Press Release, dated November 10, 2025](ex-991acumenpharmaceutic.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **Acumen Pharmaceuticals, Inc.** | **Acumen Pharmaceuticals, Inc.** |
| Dated: November 10, 2025 | By: | /s/ Derek Meisner |
|  |  | Derek Meisner<br>*Chief Legal Officer*  |

---

## Exhibit 99.1

![](ex-991acumenpharmaceutic001.jpg)

EXHIBIT 99.1 Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors NEWTON, Mass., Nov. 10, 2025 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced George Golumbeski, Ph.D., has joined its Board of Directors as Chairman. Dr. Golumbeski brings more than 30 years of experience in the biopharmaceuticals industry, with extensive expertise in portfolio strategy, strategic collaborations and licensing, and M&A. The addition of Dr. Golumbeski brings the Acumen Board to eight members. "I am very pleased to welcome Dr. Golumbeski to the Acumen Board as we continue to work to develop novel disease-modifying treatments for Alzheimer's disease," said Daniel O'Connell, Chief Executive Officer of Acumen Pharmaceuticals. "Dr. Golumbeski is a highly experienced biopharma leader with a strong track record in strategic initiatives and forging transformational partnerships and collaborations that have enabled the development of innovative treatment options for people with AD. George's deep expertise aligns with our current growth objectives as we anticipate important catalysts next year for our ongoing Phase 2 trial of sabirnetug and our Enhanced Brain Delivery program, both of which we believe can benefit people living with AD and drive value for shareholders." "Having seen first-hand the positive impact that innovation can have on the lives of people living with difficult-to-treat diseases, I could not be more excited to join the Acumen Board at this stage in the Company's development," said Dr. Golumbeski. "The unmet need in Alzheimer's is massive and urgently needs impactful analysis. The field is at an important inflection point. I look forward to collaborating with the other members of Acumen's Board, leadership and the entire team dedicated to advancing Acumen's programs with the goal of improving the lives of people impacted by Alzheimer's, including people with early AD, their families and caregivers." Currently, Dr. Golumbeski is dedicated to helping develop young companies at DROIA Ventures, a specialist biotech investment firm. For nearly a decade, Dr. Golumbeski served

------

![](ex-991acumenpharmaceutic002.jpg)

as Executive Vice President of Business Development at Celgene, where he was responsible for forging collaborations with biotechnology companies seeking to bring breakthrough medicines to people suffering from cancer and chronic inflammation. Prior to joining Celgene, Dr. Golumbeski held leadership positions in business development at Novartis Pharmaceuticals and Elan Pharmaceuticals. At Elan, he worked exclusively on neurology and neurodegeneration. He holds a Ph.D. in Genetics from the University of Wisconsin- Madison, conducted his post-doctoral research in molecular biology at the University of Colorado-Boulder, and holds a B.A. in Biology from the University of Virginia. About Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in people with early Alzheimer's disease, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme's proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer's disease utilizing a transferrin-receptor-targeting blood-brain barrier- penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen's goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as "believes," "expects," "anticipates," "could," "should," "would," "seeks," "aims," "plans," "potential," "will," "milestone" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning the therapeutic potential of Acumen's product candidate, sabirnetug (ACU193), including against other antibodies, the

------

![](ex-991acumenpharmaceutic003.jpg)

timing of anticipated topline results of ALTITUDE-AD, and the potential to develop a candidate to treat Alzheimer's Disease utilizing EBD technology. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen's programs are described in additional detail in Acumen's filings with the Securities and Exchange Commission ("SEC"), including in Acumen's most recent Annual Report on Form 10-K, and in subsequent filings with the SEC. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward- looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise. CONTACTS: Investors: Alex Braun abraun@acumenpharm.com Media: AcumenPR@icrhealthcare.com

------